The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline
| Autor: | Corinne Vigouroux, Lucy N Wainaina Mungai, Michelle M Jack, Tohru Yorifuji, Ekaterina Sorkina, Pik To Cheung, Rebecca J. Brown, Julia von Schnurbein, Kristina I. Rother, Takara L. Stanley, Nivedita Patni, David B. Dunger, Rachel Williams, Martin Wabitsch, Abhimanyu Garg, Elif A. Oral, David Araújo-Vilar |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Lipodystrophy Endocrinology Diabetes and Metabolism Clinical Biochemistry MEDLINE 030209 endocrinology & metabolism Acquired generalized lipodystrophy Biochemistry Acquired Partial Lipodystrophy 03 medical and health sciences Metreleptin chemistry.chemical_compound 0302 clinical medicine Endocrinology Internal medicine medicine Humans business.industry Generalized lipodystrophy Biochemistry (medical) Guideline medicine.disease Familial partial lipodystrophy Special Features 3. Good health 030104 developmental biology chemistry Practice Guidelines as Topic business |
| Zdroj: | The Journal of Clinical Endocrinology and Metabolism |
| ISSN: | 1945-7197 0021-972X |
| Popis: | Objective: Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications, including diabetes, hypertriglyceridemia, and steatohepatitis. Due to their rarity, most clinicians are not familiar with their diagnosis and management. This practice guideline summarizes the diagnosis and management of lipodystrophy syndromes not associated with HIV or injectable drugs. Participants: Seventeen participants were nominated by worldwide endocrine societies or selected by the committee as content experts. Funding was via an unrestricted educational grant from Astra Zeneca to the Pediatric Endocrine Society. Meetings were not open to the general public. Evidence: A literature review was conducted by the committee. Recommendations of the committee were graded using the system of the American Heart Association. Expert opinion was used when published data were unavailable or scarce. Consensus Process: The guideline was drafted by committee members and reviewed, revised, and approved by the entire committee during group meetings. Contributing societies reviewed the document and provided approval. Conclusions: Lipodystrophy syndromes are heterogeneous and are diagnosed by clinical phenotype, supplemented by genetic testing in certain forms. Patients with most lipodystrophy syndromes should be screened for diabetes, dyslipidemia, and liver, kidney, and heart disease annually. Diet is essential for the management of metabolic complications of lipodystrophy. Metreleptin therapy is effective for metabolic complications in hypoleptinemic patients with generalized lipodystrophy and selected patients with partial lipodystrophy. Other treatments not specific for lipodystrophy may be helpful as well (eg, metformin for diabetes, and statins or fibrates for hyperlipidemia). Oral estrogens are contraindicated. Multiple worldwide endocrine societies developed practice guidelines for diagnosis and management of lipodystrophy syndromes based on current evidence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|